87014-28-6

Basic information

• Product Name: Benzene, 1-nitro-2-(2,2,2-trifluoroethoxy)-
• Synonyms: Benzene, 1-nitro-2-(2,2,2-trifluoroethoxy)-;1-Nitro-2-(2,2,2-trifluoroethoxy)benzene;2-(2,2,2-Trifluoroethoxy)nitrobenzene97%
• CAS NO: 87014-28-6
• Molecular Formula: C₈H₆F₃NO₃
• Molecular Weight: 221.1333496
• Mol File: 87014-28-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzene, 1-nitro-2-(2,2,2-trifluoroethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-nitro-2-(2,2,2-trifluoroethoxy)-(87014-28-6)
• EPA Substance Registry System: Benzene, 1-nitro-2-(2,2,2-trifluoroethoxy)-(87014-28-6)

Safety Data

• Hazardous Substances Data: 87014-28-6(Hazardous Substances Data)

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 88-73-3 2-Chloronitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 433-06-7 2,2,2-Trifluoroethyl p-toluenesulfonate 
• 88-75-5 2-hydroxynitrobenzene 
• 420-87-1 sodium 2,2,2-trifluoroethanolate 
• 528-29-0 1,2-Dinitrobenzene 
• 609-73-4 o-nitroiodobenzene 
• 577-19-5 2-nitrophenyl bromide 

Downstream Products

• 57946-60-8 2-(2',2',2'-trifluoroethoxy)aniline 
• 917514-08-0 4-heptafluoroisopropyl-2-(2,2,2-trifluoroethoxy)aniline 
• 62149-83-1 2-(2,2,2-trifluoroethoxy)aniline hydrochloride 
• 178671-99-3 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 1027544-70-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid ethyl ester 
• 1025909-31-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid 
• 334930-12-0 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-4-[3-(N-phthalimido)-propyl]-piperazine 
• 334930-13-1 1-(3-Aminopropyl)-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 

Relevant articles and documents

BrettPhos ligand supported palladium-catalyzed C-O bond formation through an electronic pathway of reductive elimination: Fluoroalkoxylation of activated aryl halides

We report an unprecedented BrettPhos ligand supported Pd-catalyzed C-O bond-forming reaction of activated aryl halides with primary fluoroalkyl alcohols. We demonstrate that the Phosphine ligand (BrettPhos) possesses the property of altering the mechanistic pathway of reductive elimination from nucleophile to nucleophile. The Pd/BrettPhos catalyst system facilitates the reductive elimination of the oxygen nucleophile through an electronic pathway.

PYRROLO 3,2-c]QUINOLINE DERIVATIVES CONTAINING HALOALKOXY GROUP AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to a novel pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group, represented by Formula I, their pharmaceutically acceptable salts; process for preparation thereof; and pharmaceutical composition thereof for treati

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.